Entrada Therapeutics, Inc. (TRDA)
Automate Your Wheel Strategy on TRDA
With Tiblio's Option Bot, you can configure your own wheel strategy including TRDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRDA
- Rev/Share 4.1929
- Book/Share 10.1588
- PB 0.7481
- Debt/Equity 0.1366
- CurrentRatio 21.8758
- ROIC 0.009
- MktCap 288445992.0
- FreeCF/Share -1.4123
- PFCF -4.9724
- PE 12.5968
- Debt/Assets 0.1172
- DivYield 0
- ROE 0.0584
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 2
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRDA | ROTH MKM | -- | Buy | -- | $29 | Dec. 6, 2024 |
News
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.
Read More
Entrada Therapeutics Reports First Quarter 2025 Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the first quarter ended March 31, 2025, and highlighted recent business …
Read More
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational …
Read More
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. “We …
Read More
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase …
Read More
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share.
Read More
About Entrada Therapeutics, Inc. (TRDA)
- IPO Date 2021-10-29
- Website https://www.entradatx.com
- Industry Biotechnology
- CEO Mr. Dipal Doshi
- Employees 183